Malin Corporation plc
Malin Corporation plc
03/02/2020 | Press release | Archived content
Immunocore Secures $130 Million Series B Financing
Immunocore Secures $130 Million Series B Financing
Led by General Atlantic, funding will expand novel scientific platform and advance proprietary pipeline of ImmTAX™ molecules into the clinic
(Oxfordshire, UK and Conshohocken, Pa. and Rockville, Md., US, 2 March 2020) Immunocore, a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announced the completion of its Series B private financing round, generating more than $130 million.
Read the full press release
Company website
Malin Corporation plc published this content on March 02, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 22, 2025 at 09:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]